Botulinum toxin type A in prophylactic treatment of migraine headaches: A preliminary study

Barrientos, N.; Chana, P

Keywords: muscle, research, serotonin, disease, trial, safety, mechanism, efficacy, severity, agonist, human, male, weakness, tolerability, frequency, migraine, agent, toxin, adult, antiinflammatory, female, outcomes, placebo, drug, article, analysis, blind, test, controlled, sum, clinical, rank, analgesic, forehead, study, priority, journal, double, a, procedure, randomized, nonsteroid, botulinum

Abstract

The purpose of this study was to determine the safety and efficacy of botulinum toxin type A (BOTOX; Allergan, Irvine, USA) in migraine prophylaxis. We performed a double-blind, randomized, 90-day placebo-controlled study that enrolled 30 adult migraineurs. Patients received 50 units botulinum toxin type A (n=15) or placebo (n=15). Outcome measures were monthly frequency and duration of migraine attacks and the number of severe attacks. Botulinum toxin type A produced significantly greater reductions in the frequency of migraine attacks of any severity at Day 90 (-3.14 vs. - 0.53; p<0.05) and in the frequency of severe migraine attacks at Days 60 (- 1.4 vs. -0.54; p<0.05) and 90 (-1.8 vs. -0.20; p<0.02). One patient in the botulinum toxin type A group experienced mild, transient frontalis muscle weakness lasting approximately 30 days. Botulinum toxin type A injections were well tolerated and provided effective migraine prophylaxis in these patients.

Más información

Título según SCOPUS: Botulinum toxin type A in prophylactic treatment of migraine headaches: A preliminary study
Título de la Revista: JOURNAL OF HEADACHE AND PAIN
Volumen: 4
Número: 3
Editorial: BMC
Fecha de publicación: 2003
Página de inicio: 146
Página final: 151
Idioma: English
URL: http://www.scopus.com/inward/record.url?eid=2-s2.0-0345802553&partnerID=q2rCbXpz
DOI:

10.1007/s10194-003-0049-2

Notas: SCOPUS